

## GOV. MSG. NO. 1245

EXECUTIVE CHAMBERS KE KE'ENA O KE KIA'ĀINA

JOSH GREEN, M.D. GOVERNOR KE KIA'ĀINA

June 29, 2023

The Honorable Ronald D. Kouchi President of the Senate, and Members of the Senate Thirty-Second State Legislature State Capitol, Room 409 Honolulu, Hawai'i 96813  The Honorable Scott K. Saiki Speaker, and Members of the House of Representatives Thirty-Second State Legislature State Capitol, Room 431 Honolulu, Hawai'i 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

This is to inform you that on June 29, 2023, the following bill was signed into law:

HB1097 HD2 SD1

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT. ACT 162

Sincerely,

oh Green M.D.

Josh Green, M.D. Governor, State of Hawaiʻi

### Approved by the Governor

on

JUN 2 9 2023

HOUSE OF REPRESENTATIVES THIRTY-SECOND LEGISLATURE, 2023 STATE OF HAWAII

2023-2323 HB1097 SD1 SMA.docx

### A BILL FOR AN ACT

ACT 162

S.D. 1

1

H.B. NO. 1097 H.D. 2

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

#### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

| 1  | SECTION 1. Section 329-14, Hawaii Revised Statutes, is          |
|----|---|
| 2  | amended as follows:   |
| 3  | 1. By amending subsection (d) to read:                          |
| 4  | "(d) [Any] Hallucinogenic substances. Unless specifically       |
| 5  | excepted or unless listed in another schedule, any material,    |
| 6  | compound, mixture, or preparation that contains any quantity of |
| 7  | the following hallucinogenic substances, including their salts, |
| 8  | isomers, and salts of isomers, [unless specifically excepted,]  |
| 9  | whenever the existence of these salts, isomers, and salts of    |
| 10 | isomers is possible within the specific chemical designation:   |
| 11 | (1) Alpha-ethyltryptamine (AET);                                |
| 12 | (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);                    |
| 13 | (3) 2,5-dimethoxyamphetamine (2,5-DMA);                         |
| 14 | (4) 3,4-methylenedioxy amphetamine;                             |
| 15 | (5) 3,4-methylenedioxymethamphetamine (MDMA);                   |
| 16 | (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-         |
| 17 | MDA);   |

H.B. NO. <sup>1097</sup> H.D. 2 S.D. 1

| 1  | (7)  | 3,4-methylenedioxy-N-ethylamphetamine (MDE);          |
|----|------|---|
| 2  | (8)  | 5-methoxy-3,4-methylenedioxy-amphetamine;             |
| 3  | (9)  | 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);  |
| 4  | (10) | 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);          |
| 5  | (11) | 3,4,5-trimethoxy amphetamine;                         |
| 6  | (12) | Bufotenine;   |
| 7  | (13) | 4-methoxyamphetamine (PMA);                           |
| 8  | (14) | Diethyltryptamine;                                    |
| 9  | (15) | Dimethyltryptamine;                                   |
| 10 | (16) | <pre>4-methyl-2,5-dimethoxy-amphetamine;</pre>        |
| 11 | (17) | Gamma hydroxybutyrate (GHB) (some other names include |
| 12 |      | gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-      |
| 13 |      | hydroxybutanoic acid; sodium oxybate; sodium          |
| 14 |      | oxybutyrate);   |
| 15 | (18) | Ibogaine;   |
| 16 | (19) | Lysergic acid diethylamide;                           |
| 17 | (20) | Marijuana;  |
| 18 | (21) | Parahexyl;  |
| 19 | (22) | Mescaline;  |
| 20 | (23) | Peyote;   |
| 21 | (24) | N-ethyl-3-piperidyl benzilate;                        |

2023-2323 HB1097 SD1 SMA.docx

|      |     | 1097   |
|------|-----|--------|
| H.B. | N() | H.D. 2 |
|      |     | S.D. 1 |

| 1  | (25) | N-methyl-3-piperidyl benzilate;                        |
|----|------|--|
| 2  | (26) | Psilocybin;  |
| 3  | (27) | Psilocyn;  |
| 4  | (28) | 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);       |
| 5  | (29) | Ethylamine analog of phencyclidine (PCE);              |
| 6  | (30) | Pyrrolidine analog of phencyclidine (PCPy, PHP);       |
| 7  | (31) | Thiophene analog of phencyclidine (TPCP; TCP);         |
| 8  | (32) | Gamma-butyrolactone, including butyrolactone;          |
| 9  |      | butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone   |
| 10 |      | dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; |
| 11 |      | 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-   |
| 12 |      | hydroxybutyric acid lactone; 3-hydroxybutyric acid     |
| 13 |      | lactone and 4-hydroxybutanoic acid lactone with        |
| 14 |      | Chemical Abstract Service number 96-48-0 when any such |
| 15 |      | substance is intended for human ingestion;             |
| 16 | (33) | 1,4 butanediol, including butanediol; butane-1,4-diol; |
| 17 |      | 1,4- butylenes glycol; butylene glycol; 1,4-           |
| 18 |      | dihydroxybutane; 1,4- tetramethylene glycol;           |
| 19 |      | tetramethylene glycol; tetramethylene 1,4- diol with   |
| 20 |      | Chemical Abstract Service number 110-63-4 when any     |
| 21 |      | such substance is intended for human ingestion;        |

2023-2323 HB1097 SD1 SMA.docx

| 1                                | (34)                         | 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),  |
|----------------------------------|------------------------------|---|
| 2                                |                              | its optical isomers, salts, and salts of isomers;   |
| 3                                | (35)                         | N-benzylpiperazine (BZP; 1-benzylpiperazine) <u>,</u> its   |
| 4                                |                              | optical isomers, salts, and salts of isomers;   |
| 5                                | (36)                         | 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its  |
| 6                                |                              | optical isomers, salts, and salts of isomers;   |
| 7                                | (37)                         | Alpha-methyltryptamine (AMT) [, its isomers, salts, and   |
| 8                                |                              | salts of isomers];  |
| 9                                | (38)                         | 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT)[ <del>, its</del>  |
| 10                               |                              | <pre>isomers, salts, and salts of isomers];</pre>   |
| 11                               | (39)                         | Salvia divinorum;   |
|                                  |                              | Columnation D   |
| 12                               | (40)                         | Salvinorin A;   |
| 12<br>13                         | (40)                         | Divinorin A;  |
|                                  |                              |   |
| 13                               | (41)                         | Divinorin A;  |
| 13<br>14                         | (41)                         | Divinorin A;<br>5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some   |
| 13<br>14<br>15                   | (41)                         | <pre>Divinorin A;<br/>5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some<br/>trade or other names: 5-methoxy-3-[2-<br/>(dimethylamino)ethyl]indole; 5-MeO-DMT);</pre>  |
| 13<br>14<br>15<br>16             | (41)<br>(42)                 | <pre>Divinorin A;<br/>5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some<br/>trade or other names: 5-methoxy-3-[2-<br/>(dimethylamino)ethyl]indole; 5-MeO-DMT);</pre>  |
| 13<br>14<br>15<br>16<br>17       | (41)<br>(42)<br>(43)         | <pre>Divinorin A;<br/>5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some<br/>trade or other names: 5-methoxy-3-[2-<br/>(dimethylamino)ethyl]indole; 5-MeO-DMT);<br/>2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);</pre>  |
| 13<br>14<br>15<br>16<br>17<br>18 | (41)<br>(42)<br>(43)<br>(44) | <pre>Divinorin A;<br/>5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some<br/>trade or other names: 5-methoxy-3-[2-<br/>(dimethylamino)ethyl]indole; 5-MeO-DMT);<br/>2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);<br/>2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);</pre> |

2023-2323 HB1097 SD1 SMA.docx

| 1  | (47) | 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T- |
|----|------|--|
| 2  |      | 2);  |
| 3  | (48) | 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine    |
| 4  |      | (2C-T-4);  |
| 5  | (49) | 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);              |
| 6  | (50) | 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);     |
| 7  | (51) | 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); |
| 8  | (52) | 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-                   |
| 9  |      | methoxybenzyl)ethanamine, its optical, positional, and |
| 10 |      | geometric isomers, salts, and salts of isomers (Other  |
| 11 |      | names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);           |
| 12 | (53) | 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-                 |
| 13 |      | methoxybenzyl)ethanamine, its optical, positional, and |
| 14 |      | geometric isomers, salts, and salts of isomers (Other  |
| 15 |      | names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); [and]    |
| 16 | (54) | 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-                  |
| 17 |      | methoxybenzyl)ethanamine, its optical, positional, and |
| 18 |      | geometric isomers, salts, and salts of isomers (Other  |
| 19 |      | names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) [-];      |
| 20 | (55) | N-ethylhexedrone, its optical, positional, and         |
| 21 |      | geometric isomers, salts, and salts of isomers (Other  |



1097 H.D. 2 S.D. 1 H.B. NO.

| 1  |      | names: [alpha]-ethylaminohexanophenone; 2-             |
|----|------|--|
| 2  |      | (ethylamino)-1-phenylhexan-1-one);                     |
| 3  | (56) | Alpha-pyrrolidinohexanophenone, its optical,           |
| 4  |      | positional, and geometric isomers, salts, and salts of |
| 5  |      | isomers (Other names: [alpha]-PHP; [alpha]-            |
| 6  |      | pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-    |
| 7  |      | <pre>yl)hexan-1-one);</pre>                            |
| 8  | (57) | 4-methyl-alpha-ethylaminopentiophenone, its optical,   |
| 9  |      | positional, and geometric isomers, salts, and salts of |
| 10 |      | isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-     |
| 11 |      | <pre>methylphenyl)pentan-1-one);</pre>                 |
| 12 | (58) | 4'-methyl-alpha-pyrrolidinohexiophenone, its optical,  |
| 13 |      | positional, and geometric isomers, salts, and salts of |
| 14 |      | isomers (Other names: MPHP; 4'-methyl-alpha-           |
| 15 |      | pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-        |
| 16 |      | (pyrrolidin-1-yl)hexan-1-one);                         |
| 17 | (59) | Alpha-pyrrolidinoheptaphenone, its optical,            |
| 18 |      | positional, and geometric isomers, salts, and salts of |
| 19 |      | isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-   |
| 20 |      | <pre>yl)heptan-1-one);</pre>                           |

# 2023-2323 HB1097 SD1 SMA.docx

| 1  | (60)      | 4'-chloro-alpha-pyrrolidinovalerophenone, its optical,  |
|----|-----------|---|
| 2  |           | positional, and geometric isomers, salts, and salts of  |
| 3  |           | isomers (Other names: 4-chloro-[alpha]-PVP; 4'-         |
| 4  |           | chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-          |
| 5  |           | chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); and     |
| 6  | (61)      | 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one      |
| 7  |           | (methoxetamine, MXE)."                                  |
| 8  | 2.        | By amending subsection (g) to read:                     |
| 9  | " (g)     | [Any] Cannabinoids. Unless specifically excepted or     |
| 10 | unless li | sted in another schedule, any of the following          |
| 11 | cannabino | ids, including their salts, isomers, and salts of       |
| 12 | isomers,  | [unless specifically excepted,] whenever the existence  |
| 13 | of these  | salts, isomers, and salts of isomers is possible within |
| 14 | the speci | fic chemical designation:                               |
| 15 | (1)       | Tetrahydrocannabinols; meaning tetrahydrocannabinols    |
| 16 |           | naturally contained in a plant of the genus Cannabis    |
| 17 |           | (cannabis plant), as well as synthetic equivalents of   |
| 18 |           | the substances contained in the plant, or in the        |
| 19 |           | resinous extractives of Cannabis, sp. or synthetic      |
| 20 |           | substances, derivatives, and their isomers with         |
| 21 |           | similar chemical structure and pharmacological          |

2023-2323 HB1097 SD1 SMA.docx

Page 8

H.B. NO. <sup>1097</sup> H.D. 2 S.D. 1

| 1  |     | activity to those substances contained in the plant,   |
|----|-----|--|
| 2  |     | such as the following: Delta 1 cis or trans            |
| 3  |     | tetrahydrocannabinol, and their optical isomers; Delta |
| 4  |     | 6 cis or trans tetrahydrocannabinol, and their optical |
| 5  |     | isomers; and Delta 3,4 cis or trans-                   |
| 6  |     | tetrahydrocannabinol, and its optical isomers (since   |
| 7  |     | nomenclature of these substances is not                |
| 8  |     | internationally standardized, compounds of these       |
| 9  |     | structures, regardless of numerical designation of     |
| 10 |     | atomic positions, are covered);                        |
| 11 | (2) | Naphthoylindoles; meaning any compound containing a 3- |
| 12 |     | (1-naphthoyl)indole structure with substitution at the |
| 13 |     | nitrogen atom of the indole ring by a alkyl,           |
| 14 |     | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
| 15 |     | 1-(N-methyl-2-piperidinyl)methyl or 2-(4-              |
| 16 |     | morpholinyl)ethyl group, whether or not further        |
| 17 |     | substituted in the indole ring to any extent and       |
| 18 |     | whether or not substituted in the naphthyl ring to any |
| 19 |     | extent;  |
| 20 | (3) | Naphthylmethylindoles; meaning any compound containing |
| 21 |     | a 1H-indol-3-yl-(1-naphthyl) methane structure with    |

# 2023-2323 HB1097 SD1 SMA.docx

H.B. NO. <sup>1097</sup> H.D. 2 S.D. 1

substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

Naphthoylpyrroles; meaning any compound containing a 8 (4) 9 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by a alkyl, 10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 11 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) 12 ethyl group whether or not further substituted in the 13 pyrrole ring to any extent, whether or not substituted 14 in the naphthyl ring to any extent; 15

16 (5) Naphthylmethylindenes; meaning any compound containing
17 a naphthylideneindene structure with substitution at
18 the 3-position of the indene ring by a alkyl,
19 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
20 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
21 ethyl group whether or not further substituted in the

### 2023-2323 HB1097 SD1 SMA.docx

Page 10

|    | Page 10 | H.B. NO. <sup>1097</sup><br>H.D. 2<br>S.D. 1           |
|----|---------|--|
| 1  |         | indene ring to any extent, whether or not substituted  |
| 2  |         | in the naphthyl ring to any extent;                    |
| 3  | (6)     | Phenylacetylindoles; meaning any compound containing a |
| 4  |         | 3-phenylacetylindole structure with substitution at    |
| 5  |         | the nitrogen atom of the indole ring by a alkyl,       |
| 6  |         | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
| 7  |         | 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) |
| 8  |         | ethyl group whether or not further substituted in the  |
| 9  |         | indole ring to any extent, whether or not substituted  |
| 10 |         | in the phenyl ring to any extent;                      |
| 11 | (7)     | Cyclohexylphenols; meaning any compound containing a   |
| 12 |         | 2-(3-hydroxycyclohexyl) phenol structure with          |
| 13 |         | substitution at the 5-position of the phenolic ring by |
| 14 |         | a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,         |
| 15 |         | cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or  |
| 16 |         | 2-(4-morpholinyl) ethyl group whether or not           |
| 17 |         | substituted in the cyclohexyl ring to any extent;      |
| 18 | (8)     | Benzoylindoles; meaning any compound containing a 3-   |
| 19 |         | (benzoyl) indole structure with substitution at the    |
| 20 |         | nitrogen atom of the indole ring by a alkyl,           |
| 21 |         | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
|    |         |  |

# 2023-2323 HB1097 SD1 SMA.docx



| 1  |        | 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-                     |
|----|--------|---|
| 2  |        | morpholinyl) ethyl group whether or not further                 |
| 3  |        | substituted in the indole ring to any extent and                |
| 4  |        | whether or not substituted in the phenyl ring to any            |
| 5  |        | extent;   |
| 6  | (9)    | [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)                   |
| 7  |        | pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-                      |
| 8  | •<br>• | naphthalenylmethanone (another trade name is WIN                |
| 9  |        | 55,212-2);  |
| 10 | (10)   | (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-                  |
| 11 |        | methyloctan-2-yl)-6a,7,10,10a-                                  |
| 12 |        | tetrahydrobenzo[c]chromen-1-ol (Other trade names are:          |
| 13 |        | HU-210/HU-211);   |
| 14 | (11)   | Tetramethylcyclopropanoylindoles; meaning any compound          |
| 15 |        | containing a 3-tetramethylcyclopropanoylindole                  |
| 16 |        | structure with substitution at the nitrogen atom of             |
| 17 |        | the indole ring by an alkyl, haloalkyl, cyanoalkyl,             |
| 18 |        | alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-               |
| 19 |        | <pre>methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,</pre> |
| 20 |        | 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-               |
| 21 |        | morpholinyl)methyl, or tetrahydropyranylmethyl group,           |

2023-2323 HB1097 SD1 SMA.docx

### H.B. NO. <sup>1097</sup> H.D. 2 S.D. 1

| 1  |      | whether or not further substituted in the indole ring  |
|----|------|--|
| 2  |      | to any extent and whether or not substituted in the    |
| 3  |      | tetramethylcyclopropyl ring to any extent;             |
| 4  | (12) | N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,    |
| 5  |      | its optical, positional, and geometric isomers, salts, |
| 6  |      | and salts of isomers (Other names: APINACA, AKB48);    |
| 7  | (13) | Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its    |
| 8  |      | optical, positional, and geometric isomers, salts, and |
| 9  |      | salts of isomers (Other names: PB-22; QUPIC);          |
| 10 | (14) | Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-           |
| 11 |      | carboxylate, its optical, positional, and geometric    |
| 12 |      | isomers, salts, and salts of isomers (Other names: 5-  |
| 13 |      | fluoro-PB-22; 5F-PB-22);                               |
| 14 | (15) | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-             |
| 15 |      | fluorobenzyl)-1H-indazole-3-carboxamide, its optical,  |
| 16 |      | positional, and geometric isomers, salts, and salts of |
| 17 |      | isomers (Other names: AB-FUBINACA);                    |
| 18 | (16) | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-  |
| 19 |      | indazole-3-carboxamide, its optical, positional, and   |
| 20 |      | geometric isomers, salts, and salts of isomers (Other  |
| 21 |      | names: ADB-PINACA);                                    |

2023-2323 HB1097 SD1 SMA.docx

|   |     |     | 1097             |
|---|-----|-----|------------------|
| Η | .В. | NO. | H.D. 2<br>S.D. 1 |
|   |     |     | 3.D. I           |

| 1  | (17) | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-                  |
|----|------|--|
| 2  |      | (cyclohexylmethyl)-1H-indazole-3-carboxamide, its        |
| 3  |      | optical, positional, and geometric isomers, salts, and   |
| 4  |      | salts of isomers (Other names: AB-CHMINACA);             |
| 5  | (18) | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-        |
| 6  |      | indazole-3-carboxamide, and geometric isomers, salts,    |
| 7  |      | and salts of isomers (Other names: AB-PINACA);           |
| 8  | (19) | [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-       |
| 9  |      | yl)methanone, and geometric isomers, salts, and salts    |
| 10 |      | of isomers (Other names: THJ-2201);                      |
| 11 | (20) | Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-    |
| 12 |      | valinate, and geometric isomers, salts, and salts of     |
| 13 |      | isomers (Other names: FUB-AMB, Methyl 2-(1-(4-           |
| 14 |      | fluorobenzyl)-1H-indazole-3-carboxamido)-3-              |
| 15 |      | <pre>methylbutanoate, MMB-FUBINACA, AMB-FUBINACA);</pre> |
| 16 | (21) | (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-          |
| 17 |      | carboxamido)-3-methylbutanoate, and geometric isomers,   |
| 18 |      | salts, and salts of isomers (Other names: 5-fluoro-      |
| 19 |      | AMB, 5-fluoro-AMP);                                      |
| 20 | (22) | N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-     |
| 21 |      | indazole-3-carboxamide, and geometric isomers, salts,    |

2023-2323 HB1097 SD1 SMA.docx

| •  | *    |   |
|----|------|---|
| 1  |      | and salts of isomers (Other names: AKB48 N-(5-                      |
| 2  |      | fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl              |
| 3  |      | analog, 5F-APINACA);  |
| 4  | (23) | N-adamantyl-1-fluoropentylindole-3-Carboxamide, and                 |
| 5  |      | geometric isomers, salts, and salts of isomers (Other               |
| 6  |      | names: STS-135, 5F-APICA; 5-fluoro-APICA);                          |
| 7  | (24) | Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-                     |
| 8  |      | carboxylate, and geometric isomers, salts, and salts                |
| 9  |      | of isomers (Other names: NM2201; CBL2201);                          |
| 10 | (25) | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-                         |
| 11 |      | (cyclohexylmethyl)-1H-indazole-3-carboxamide, and                   |
| 12 |      | geometric isomers, salts, and salts of isomers (Other               |
| 13 |      | names: MAB-CHMINACA and ADB-CHMINACA);                              |
| 14 | (26) | Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-                         |
| 15 |      | carboxamido]-3,3-dimethylbutanoate (Other names: 5F-                |
| 16 |      | ADB, [ <del>5-flouro-ADB,</del> ] <u>5-fluoro-ADB,</u> and 5F-MDMB- |
| 17 |      | PINACA), its optical, positional, and geometric                     |
| 18 | -    | isomers, salts, and salts of isomers;                               |
| 19 | (27) | 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-lH-indazole-               |
| 20 |      | 3-carboxamide, its optical, positional, and geometric               |
| 21 |      | isomers, salts, and salts of isomers (Other names:                  |
|    |      |   |



Page 15

| 1  |      | SGT-78; 4-CN-CUMYL BINACA; 4-CN-CUMYL-BUTINACA; CUMYL- |
|----|------|--|
| 2  |      | CB-PINACA; CUMYL-CYBINACA; 4-cyano-CUMYL-BUTINACA;     |
| 3  |      | CUMYL-4CN-BINACA);                                     |
| 4  | (28) | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-             |
| 5  |      | fluoropentyl)-1H-indazole-3-carboxamide (Other name:   |
| 6  |      | 5F-AB-PINACA);   |
| 7  | (29) | Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-            |
| 8  |      | carboxamido)-3-methylbutanoate (Other names: MMB-      |
| 9  |      | CHMICA; AMB-CHMICA);                                   |
| 10 | (30) | 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-         |
| 11 |      | pyrrolo[2,3-b]pyridine-3-carboxamide (Other names: 5F- |
| 12 |      | CUMYL-P7AICA); [and]                                   |
| 13 | (31) | Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole- |
| 14 |      | 3-carboxamido)butanoate (MDMB-4en-PINACA) [-];         |
| 15 | (32) | Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-             |
| 16 |      | carboxamido)-3,3-dimethylbutanoate (Other name: 5F-    |
| 17 |      | EDMB-PINACA);  |
| 18 | (33) | Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)- |
| 19 |      | 3,3-dimethylbutanoate (Other names: 5F-MDMB-PICA; 5F-  |
| 20 | · .  | MDMB-2201);  |

| 1  | (34)  | N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-                     |  |
|----|---|--|--|
| 2  |   | carboxamide (Other names: FUB-AKB48; FUB-APINACA;                        |  |
| 3  |   | AKB48 N-(4-FLUOROBENZYL));   |  |
| 4  | (35)  | <u>1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-</u>                    |  |
| 5  |   | indazole-3-carboxamide (Other names: 5F-CUMYL-PINACA;                    |  |
| 6  |   | SGT-25); and   |  |
| 7  | (36)  | (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-                              |  |
| 8  |   | tetramethylcyclopropyl)methanone (Other name: FUB-                       |  |
| 9  |   | <u>144).</u> "   |  |
| 10 | SECTION 2. Section 329-20, Hawaii Revised Statutes, is        |  |  |
| 11 | amended by amending subsection (b) to read as follows:        |  |  |
| 12 | " (b)   | Depressants. [ <del>Any</del> ] <u>Unless specifically excepted or</u>   |  |
| 13 | <u>unless li</u>  | sted in another schedule, any material, compound,                        |  |
| 14 | mixture,  | or preparation [ <del>which</del> ] <u>that</u> contains any quantity of |  |
| 15 | the follo   | wing substances, including its salts, isomers, esters,                   |  |
| 16 | ethers, and salts of isomers, whenever the existence of these |  |  |
| 17 | isomers,  | esters, ethers, and salts is possible within the                         |  |
| 18 | specific  | chemical designation, that has a degree of danger or                     |  |
| 19 | probable  | danger associated with a depressant effect on the                        |  |
| 20 | central n   | ervous system:   |  |
| 21 | (1)   | Alprazolam;  |  |

# 2023-2323 HB1097 SD1 SMA.docx

| 1  | (2)                  | Barbital;         |                    |           |
|----|----------------------|-------------------|--------------------|-----------|
| 2  | (3)                  | Brexanolone;      |                    |           |
| 3  | (4)                  | Bromazepam;       |                    |           |
| 4  | (5)                  | Butorp            | hanol;             |           |
| 5  | (6)                  | Camaze            | pam;               |           |
| 6  | (7)                  | Cariso            | prodol;            |           |
| 7  | (8)                  | Chlora            | l betaine;         |           |
| 8  | (9)                  | Chlora            | l hydrate;         |           |
| 9  | (10)                 | Chlordiazepoxide; |                    |           |
| 10 | (11)                 | Clobazam;         |                    |           |
| 11 | (12)                 | Clonaz            | epam;              |           |
| 12 | (13)                 | Clorazepate;      |                    |           |
| 13 | (14)                 | Clotiazepam;      |                    |           |
| 14 | (15)                 | Cloxaz            | olam;              |           |
| 15 | (16)                 | Darido            | rexant;            |           |
| 16 | [ <del>(16)</del> ]  | (17)              | Delorazepam;       |           |
| 17 | [ <del>(17)</del> ]  | (18)              | Diazepam;          |           |
| 18 | [ <del>(18)</del> ]  | (19)              | Dichloralphenazone | (Midrin); |
| 19 | [ <del>-(19)</del> ] | (20)              | Estazolam;         |           |
| 20 | [ <del>(20)</del> ]  | (21)              | Ethchlorvynol;     |           |
| 21 | [ <del>(21)</del> ]  | (22)              | Ethinamate;        | ·         |

2023-2323 HB1097 SD1 SMA.docx

- 1 [(22)] (23) Ethyl loflazepate;
- 2 [<del>(23)</del>] (24) Fludiazepam;
- 3 [<u>(24)</u>] (25) Flunitrazepam;
- 4 [<del>(25)</del>] (26) Flurazepam;
- 5 [(26)] (27) Fospropofol (Lusedra);
- 6 [<del>(27)</del>] (28) Halazepam;
- 7 [<del>(28)</del>] (29) Haloxazolam;
- 8 [<u>(29)</u>] (30) Ketazolam;
- 9 [(30)] (31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-
- 10 5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-
- 11 2-y1)cyclopropane-1-carboxamide);
- 12 [-(31)] (32) Loprazolam;
- 13 [<del>(32)</del>] (33) Lorazepam;
- 14 [<del>(33)</del>] (34) Lormetazepam;
- 15 [<del>(34)</del>] (35) Mebutamate;
- 16 [<del>(35)</del>] (36) Medazepam;
- 17 [<del>(36)</del>] (37) Meprobamate;
- 18 [<del>(37)</del>] (38) Methohexital;
- **19** [(38)] (39) Methylphenobarbital (mephorbarbital);
- 20 [<del>(39)</del>] (40) Midazolam;
- 21 [<del>(40)</del>] (41) Nimetazepam;



### 1097 H.D. 2 S.D. 1 H.B. NO.

| 1  | [ <del>(41)</del> ] <u>(42)</u> | Nitrazepam;                                 |
|----|---------------------------------|---|
| 2  | [ <del>(42)</del> ] <u>(43)</u> | Nordiazepam;                                |
| 3  | [ <del>(43)</del> ] <u>(44)</u> | Oxazepam;                                   |
| 4. | [ <del>(44)</del> ] <u>(45)</u> | Oxazolam;                                   |
| 5  | [ <del>(45)</del> ] <u>(46)</u> | Paraldehyde;                                |
| 6  | [ <del>(46)</del> ] <u>(47)</u> | Petrichloral;                               |
| 7  | [ <del>(47)</del> ] <u>(48)</u> | Phenobarbital;                              |
| 8  | [ <del>(48)</del> ] <u>(49)</u> | Pinazepam;                                  |
| 9  | [ <del>(49)</del> ] <u>(50)</u> | Prazepam;                                   |
| 10 | [ <del>(50)</del> ] <u>(51)</u> | Quazepam;                                   |
| 11 | [ <del>(51)</del> ] <u>(52)</u> | Remimazolam;                                |
| 12 | [ <del>(52)</del> ] <u>(53)</u> | Suvorexant;                                 |
| 13 | [ <del>(53)</del> ] <u>(54)</u> | Temazepam;                                  |
| 14 | [ <del>(54)</del> ] <u>(55)</u> | Tetrazepam;                                 |
| 15 | [ <del>(55)</del> ] <u>(56)</u> | Triazolam;                                  |
| 16 | [ <del>(56)</del> ] <u>(57)</u> | Zaleplon;                                   |
| 17 | [ <del>(57)</del> ] <u>(58)</u> | Zolpidem; and                               |
| 18 | [ <del>(58)</del> ] <u>(59)</u> | Zopiclone (Lunesta)."                       |
| 19 | SECTION 3.                      | Section 329-22, Hawaii Revised Statutes, is |
| 20 | amended by amen                 | ding subsection (d) to read as follows:     |

#### 2023-2323 HB1097 SD1 SMA.docx

19

"(d) Depressants. Unless specifically exempted or 1 excluded or unless listed in another schedule, any material, 2 compound, mixture, or preparation that contains any quantity of 3 the following substances having a depressant effect on the 4 central nervous system, including its salts, isomers, and salts 5 6 of isomers: Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-7 (1) yl]butanamide) (Other names: BRV; UCB-34714; 8 Briviact) and its salts; 9 Ganaxolone (3[alpha]-hydroxy-3[beta]-methyl-5[alpha]-10 (2) 11 pregnan-20-one); [(2)] (3) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-12 propionamide], (Vimpat); 13 [(3)] (4) Lasmiditan (2,4,6-trifluoro-N-(6-(1-14 methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide); 15 16 and [(4)] (5) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic 17 acid]." 18 SECTION 4. Statutory material to be repealed is bracketed 19 and stricken. New statutory material is underscored. 20

### 2023-2323 HB1097 SD1 SMA.docx

20

1097 H.D. 2

H.B. NO.

1

H.B. NO. H.D. 2

SECTION 5. This Act shall take effect upon its approval.

### APPROVED this 29th day of June, 2023

GOVERNOR OF THE STATE OF HAWAII



#### HB No. 1097, HD 2, SD 1

### THE HOUSE OF REPRESENTATIVES OF THE STATE OF HAWAII

Date: April 27, 2023 Honolulu, Hawaii

We hereby certify that the above-referenced Bill on this day passed Final Reading in the House of Representatives of the Thirty-Second Legislature of the State of Hawaii, Regular Session of 2023.

(60

Scott K. Saiki Speaker House of Representatives

Hili , lite

Brian L. Takeshita Chief Clerk House of Representatives

### THE SENATE OF THE STATE OF HAWAI'I

Date: March 30, 2023 Honolulu, Hawai'i 96813

We hereby certify that the foregoing Bill this day passed Third Reading in the Senate

of the Thirty-Second Legislature of the State of Hawai'i, Regular Session of 2023.

President of the Senate

Clerk of the Senate